Trials / Completed
CompletedNCT00088556
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Phase 1-2a Dose-Ranging Study of the Triplet Combination of Carboplatin, Paclitaxel and TLK286 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Telik · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLK286 | Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m² |
| DRUG | carboplatin | AUC 6 mg/mL/min Once every 3 weeks |
| DRUG | paclitaxel | 200 mg/m² Once every 3 weeks |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2004-07-30
- Last updated
- 2012-05-31
Locations
52 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00088556. Inclusion in this directory is not an endorsement.